Innate Pharma H1 FY26 net loss narrows to €19.62 million; revenue rises 16.52% to €5.66 million

• Innate Pharma posted a first-half net loss of EUR 19.62 million, narrowing from EUR 21.34 million a year earlier.
• Revenue and other income rose 16.52% to EUR 5.66 million, while operating expenses fell 18.53% to EUR 24.67 million.
• Operating loss narrowed to EUR 19.01 million from EUR 25.43 million, while net financial results swung to a loss of EUR 612,000 from income of EUR 4.08 million.
• Cash and financial assets totaled EUR 21.38 million at June 30, down from EUR 44.77 million at Dec. 31.
• Sobi partnership for lacutamab closed, triggering a USD 75 million upfront; cash runway forecast through end of Q1 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202609170100BIZWIRE_USPR_____20260916_BW318613) on September 17, 2026, and is solely responsible for the information contained therein.